The earnings transcript for Merck & Co., Inc. for the fourth quarter and full-year 2006 presents several key points that could influence the stock price in the short term:

1. **Strong Product Performance**: Merck reported impressive sales growth driven by new products such as Gardasil and Januvia, as well as continued strong performance from existing products like Singulair, Vytorin, and Zetia. This strong product portfolio suggests underlying strength and potential for continued growth[3].

2. **Guidance Reaffirmation**: Merck reaffirmed its 2007 guidance, indicating confidence in their ability to meet financial targets. This includes expected earnings per share of $2.51 to $2.59, excluding restructuring charges, and marketing and administrative expenses remaining flat to slightly increasing[3].

3. **Legal and Restructuring Charges**: The company recorded significant charges related to legal defense costs for VIOXX and Fosamax litigations, as well as restructuring costs. While these charges impacted the reported EPS, they do not reflect the underlying operational performance[3].

4. **Investments and Cost Management**: Merck's investments in new technologies, such as the acquisition of Sirna Therapeutics, and its focus on cost containment and efficiency improvements through Lean Six Sigma and outsourcing, suggest a strategic approach to long-term growth[3].

Given these points, the short-term impact on the stock price is likely to be positive due to the strong product performance, reaffirmed guidance, and strategic investments. However, the immediate impact of legal and restructuring charges might temper the enthusiasm slightly.

**Rating: 1**